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Abstract
This review presents the advances in the molecular biology and the pathophysiology of insulin resistance with emphasis on disturbances
in cellular glucose transport. New scientific information about the structure and function of glucotransporters from the GLUT4 and SLGT
families underline their significance in endocrinopathies and metabolic disease pathogenesis as related to insulin resistance. The new
discoveries in this area also contribute to a better understanding of the regulation of insulin receptor and post-receptor reactivity by
hormones and by drugs. They refer to the regulation of glycaemia and to its disturbances in diabetes mellitus, particularly of type 2, to
metabolic syndrome, and, in general, to the pathogenesis of many syndromes and clinical disturbances caused by insulin resistance.
Impairment of cellular glucose transport may be one of the primary aetiological factors in this respect. Therefore, studies of cellular glu-
cotransporters expression and function promise new clinical and pharmacotherapeutic developments. Progress in this area has already
been transformed into many practical proposals which are improving clinical practice. (Pol J Endocrinol 2010; 61 (4): 388–394)
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Streszczenie
W opracowaniu przedstawiono postępy biologii molekularnej oraz patofizjologię insulinooporności w aspekcie zaburzeń dokomórkowe-
go transportu glukozy. Najnowsze doniesienia naukowe dotyczące struktury i funkcji transporterów glukozy z rodziny GLUT oraz SGLT
podkreślają ich rolę w patogenezie insulinooporności prowadzącej do powstania endokrynopatii oraz chorób metabolicznych.
Nowe odkrycia w tej dziedzinie przyczyniają się również do lepszego zrozumienia wielopoziomowego działania insuliny, a także patoge-
nezy cukrzycy typu 2, zespołu metabolicznego oraz wielu schorzeń spowodowanych insulinoopornością.
Upośledzenie dokomórkowego transportu glukozy może być jednym z podstawowych czynników etiologicznych insulinooporności.
W związku z powyższym badania ekspresji i funkcji glukotransporterów zapowiadają nowe osiągnięcia kliniczne i farmakoterapeutycz-
ne. Postęp w tym zakresie przyczynił się już do powstania wielu praktycznych rozwiązań, które poprawiają praktykę kliniczną.
(Endokrynol Pol 2010; 61 (4): 388–394)
Słowa kluczowe: dokomórkowy transport glukozy, glukotransportery, ekspresja i działanie glukotransporterów, insulina, cukrzyca, insulinooporność
Insulin intracellular signal transduction:
from the receptor to genes
Insulin regulatory action involves the basic life process-
es of cells, tissues, and whole organisms. It is multifacto-
rial, perfectly organized, and functionally integrated into
successive biochemical steps and biological events gov-
erning intracellular regulation. The primary signal result-
ing from the association of the insulin molecule with the
alfa subunit of its specific receptor is transducted by the
whole system of mediating molecules and transcription-
al factors to over 100 genes [1–3]. The final result is chang-
es in gene expression, which are followed by adaptive
changes in the activity of different biochemical effectors
- metabolic and proliferative enzymes [4–6] (Fig. 1).
In this way insulin unique, pan-metabolic hormone
and drug - preserves the homeostasis of the cells and
the organism as a whole [3]. The outlines of this system
are presented in Table I.
The intracellular post-receptor regulatory influenc-
es of insulin – also, for didactic purposes - can be divid-
ed into three “arms” or directions [7–9].
They are:
— regulation (enhancement) of the cellular glucose
transport molecular system;
— adaptive changes in gene expression, with the re-
spective changes in the biosynthesis and actions of
the enzymes preserving metabolic homeostasis;
— stimulation of genes increasing the pro-mitotic, pro-
liferative, and anti-apoptotic activity of the cells [6].
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The diminished reactivity to insulin in any of the above
described “arms” of its regulatory action, or in all of them
together, is called insulin resistance [4]. It may play an aeti-
ological role in many clinical conditions (Table II).
The practical testing of these disturbances is outlined
in Table III.
It should be emphasized that insulin resistance as
a clinical syndrome may refer to one, two, or many spe-
cific steps and molecules of insulin regulatory influence,
and to one or more tissues and organs. The impairment
of the insulin action caused by its functional deficit or
by cellular resistance to insulin due to abnormalities in
the structure and function of the intracellular insulin
signal transducting molecules and the transcriptional
factors are the main pathogenetic promoter of diabetes
mellitus type 2 and metabolic syndrome [3, 10].
It should also be underlined that the primary genet-
ic abnormalities that cause insulin resistance in clinical
conditions are not well known. Experimental data based
on studies of “knock-out” animals are presented in
Table IV [1, 11].
Post-receptor insulin signalling pathway as the po-
tential aetiological site of insulin resistance.
Table I. Outline of the insulin signalling system [6–8]
Tabela I. System przekazywania sygnałów insulinowych [6–8]
Level 1 Mediator
Generation of mediator — glucoprotein molecule of the
molecules insulin receptor
— Insulin Receptor
— Substrates IRS 1, 2, 3, 4
— Phosphatydylinozytol-3 kinase (PI-3k)
— Proteins ras (H-ras, k-ras,
n-ras = 21 ras)
— GRB-2
Level 2 Protein kinases cascade
Functional transduction — Acetylo-CoA-carboxylase
of signals to the executive — ATP-citric liase
genes and enzymes — MAP-kinases
— Kinases rat 1
— Kinases Ribosomal S6 kinases
— Glycogen synthase
— Pyruvate dehydrogenase
— Triacylglycerol lipase
— Phosporylases
Figure 1. Insulin resistance in children with parents with diabetes mellitus type 2 (adapted:  Rothman D.L. et al., Proc. Natl. Acad. Sci.
USA; 1995, 92: 983–987)
Rycina 1. Insulinoopornośc u dzieci osób chorych na cukrzycę typu 2 (na podstawie:  Rothman D.L. et al., Proc. Natl. Acad. Sci. USA;
1995, 92: 983–987)
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Studies of the molecular aspects of insulin resistance
start with insulin receptors.
The molecules of cellular insulin receptors are
present in all types of cells of vertebrates, including
humans. However, their numbers expressed on cells
differ in an important fashion. It could be 40–100 recep-
tors on red blood cells, and 200,000 or more on hepato-
cytes and adipocytes [6, 7, 9]. An insulin receptor mole-
cule has the structure of glycoprotein. It is composed of
two extracellular alfa subunits which are responsible for
the active, specific binding of the insulin molecules. The
insulin receptor structure also contains two other beta
subunits which act as the catalytic protein kinases us-
ing the ATP for autophosphorylation of the tyrosine
residue within the beta subunit [11–14].
From this reaction, the multistep, functionally interrelat-
ed pathway of signalling develops. It has many directions.
The first step of the insulin action signalling is the
phosphorylation of the family of glycoproteins, which
are defined as the Insulin Receptor Substrate or IRS,
with different, specific subtypes (Fig. 2, 3).
Starting from the IRS point, insulin regulatory ac-
tions can be divided into [6, 20–22]:
— formation and functional stimulation of cellular glu-
cose transport by the specific glucotransporter fam-
ily molecules of GLUT;
— changing the expression of genes regulating the
metabolic processes;
— modifying the expression of genes promoting cell pro-
liferation and resistance to apoptosis (MAP kinases).
The removal of protein IRS in “knocked-out” mice
causes the appearance of the experimental metabolic
syndrome associated with hyperinsulinaemia [1, 10, 11].
The phosphorylated IRS molecules associate, in their SH2
domains (homology with Sre 2), molecules of successive
signals [21]. For this reason they are called “docking”
proteins. They “dock” the phosphatydylinositol-3-kinase
(PK-3K), the molecules of protein associating the growth
factor 2 (GRB-2), tyrosine phosphatase containing the SH2
groups (SHP-2), and other signal molecules [1, 6].
Disturbances of cellular glucose transport
as a candidate for the aetiological
mechanism of insulin resistance
The stimulation of the GLUT4 function results from the
translocation of the signal between IRS and the Akt
molecule [11]
The direct relation between the activity of Akt and,
stimulated by insulin, the functional translocation of
Table II. Cellular glucose transport and insulin resistance in clinical syndromes GLUT4 [6–8]
Tabela II. Dokomórkowy transport glukozy i insulinooporność w różnych klinicznych zespołach GLUT4 [6–8]
Pathophysiological type of insulin resistance
Primary insulin resistance Secondary insulin resistance Insulin resistance connected with genetic syndromes
Diabetes mellitus type 2 Obesity Progeria syndrome (Werner Syndrome)
Metabolic syndrome Diabetes mellitus type 1 and 2
Gestational diabetes mellitus Hyperlipidaemia Down, Turner, Klinefelter syndrome
Lipodystrophic diabetes mellitus Pregnancy
Trauma, stress [Ataxia-teleangactosia ?? –telangiectasia??] Syndrome
Leprechaunism Cushing Syndrome
Rabson-Mendenhall Syndrome Pheochromocytoma Friedreich ataxia
Acromegaly Alström Syndrome
Arterial hypertension Thyroid hyperfunction Laurence-Moon-Biedl Syndrome
Atherosclerosis Liver cirrhosis
Polycystic Ovary Syndrome Renal insufficiency Neuro-muscular dystrophy
Table III. Techniques for the assessment of insulin action
(insulin resistance) in vivo
Tabela III. Metody oceny działania insuliny (insulinoopor-
ności) in vivo
Dynamic techniques — endogenous insulin
Oral glucose tolerance test
Intravenous glucose tolerance test
Dynamic techniques — exogenous insulin
Insulin tolerance test
Incremental insulin infusion
Mathematical modelling techniques
Minimal model (of Bergman)
Homeostasis model assessment
Continuous infusion of glucose with model assessment
Steady-state open-loop techniques
Insulin suppression test
Euglycaemic hyperinsulinaemic glucose clamp
391
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 61 (4)
PR
A
C
E 
PO
G
LĄ
D
O
W
E
GLUT4 is very marked. PI-3K constitutes the necessary
decisive step in the regulation of the GLUT4 transloca-
tion in adipocytes. It does not, however, participate in
the GLUT4 translocation in the striated muscle contrac-
Table IV. Summary of key knockout mouse models [1, 11]
Tabela IV. Zestawienia najważniejszych modeli zaburzeń chorobowych z wykorzystaniem modyfikowanych genetycznie
myszy (knock out) [1, 11]
Mutant Phenotype
Insulin receptor knockouts
Complete Normal intrauterine growth and development
Severe hyperglycaemia and hyperketonaemia develops shortly after birth,
leading to death after 48–72 h
Muscle Elevated fat mass, serum triglycerides and free fatty acids- (FFA)
Normal blood glucose, serum insulin, and glucose tolerance
Insulin resistance, severe glucose intolerance, insulin fails to suppress hepatic glucose output
Liver Marked hyperinsulinaemia caused by increased insulin secretion/decreased insulin clearance
Metabolic phenotype improves with ageing
Reduced insulin secretion in response to glucose
b-cell Progressive impairment of glucose tolerance and mild obesity
Development of diet-sensitive obesity and insulin resistance
Hyperinsulinaemia and hypertriglyceridaemia
Brain Impaired spermatogenesis and ovarian follicle maturation
IGF-1 receptor knockout
Complete Lethal at birth owing to respiratory failure
Severe growth deficiency and widespread developmental defects
IRS protein knockouts
IRS-1 Significant growth inhibition
Mild insulin resistance and glucose intolerance but diabetes does not develop owing
to compensatory hyperinsulinaemia
IRS-2 Insulin resistance in muscle and liver coupled with abnormal b-cell function lead to diabetes
Males develop dehydration and hyperosmolar coma leading to death
Body weight and plasma glucose/insulin levels comparable to wild type
IRS-3 Insulin-stimulated glucose uptake in adipocytes from IRS-3 knockout mice similar to wild type
Mild defects in growth in male mice
IRS-4 Mild defects in reproduction and slight impairments in glucose homeostasis
Glucose transporter knockouts
GLUT4 Insulin resistance with mild impairment of glucose tolerance, growth retardation,
and decreased fat tissue deposition
Hyperinsulinaemia, cardiac hypertrophy, decreased levels of lactate and FFA
GLUT4 Insulin resistant, fasting hyperglycaemia, glucose intolerance — effects more severe than
in muscle-specific insulin receptor knockout
GLUT4 Markedly impaired insulin-stimulated glucose uptake in adipocytes
(Adipose) Insulin resistance in muscle and liver leading to glucose intolerance and hyperinsulinaemia
Insulin/IGF-1 signalling protein knockout
Knockout of PI Increased insulin sensitivity, hypoglycaemia, and increased glucose transport caused
3-kinase by switch to alternative pathway (p50)
p85 regulatory subunit Demonstrates role for PI 3-kinase in glucose homeostasis
Akt/PKB+2 Insulin resistance in muscle and liver coupled with increased pancreatic islet mass
(Complete) Glucose intolerant and hyperinsulinaemia
tion. Therefore, an additional signalling pathway ex-
ists, also regulated by the insulin receptor. This is the
pathway involving the protein CAP and Cbl molecules.
The exact mechanism of these reactions is not well
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known. It is known that the specialized “cavities” cov-
ered with clathrine and the additional molecular regu-
lator-dopamine participate in these actions. Cells with
low specialization are characterized by the predomi-
nance of GLUTl expression. Interestingly, b-cells of pan-
creatic islets and hepatocytes present significant GLUT2
expression. This transporter has relatively low transport
capacity. The influence of insulin on GLUT4 activity is
based mainly on the activation of PI-3K, which is much
faster and more efficient. It is assumed that in glucose
transport, two speed levels can be distinguished.
The first speed relates to the metabolism of glucose in
preprandial circumstances, without insulin stimulation
- mainly GLUT1 and 2. The second level is due to the sig-
nificant and fast glucose absorption caused by the rise of
insulin secretion and concentration in postprandial con-
ditions. This is mainly the case of GLUT4. Both GLUT1
and GLUT4 glucotransporters exhibit similar turnover
rates, about 20,000 molecules per minute. Km for GLUT4
glucose is, however, lower (2–7 mmol) than for GLUTl
(20–23 mmol). In insulin-sensitive tissues GLUT4 domi-
nates in terms of quantity and activity [30–32]. It can be
inhibited by cytochalasin and bis-mannose analogues.
The increase of cellular glucose transport determines
the rate of delivery of the glucose as the specific substrate
for metabolic utilization. The stimulation of the cellular
glucose transport system by insulin is harmonized with
the increase in intracellular glucose utilization for anabol-
ic and energy production, biochemical transformations,
and for inhibition of catabolic processes like glucogenoly-
sis and gluconeogenesis and for augmentation of the bio-
synthesis of proteins and triglycerides [12]. It is instantly
reflected by the extracellular glucose concentration with-
in its homeostatic, normoglycaemic level (Fig. 4, 5). Be-
sides the metabolic effects, insulin, by stimulating the mi-
togen activated protein kinases (MAP kinases), is promot-
ing the cells’ survival and proliferation [13, 15].
In this particular mitogenic process, additional reg-
ulatory mechanisms may increase the action of insulin.
Human cells expose the specific receptors for insulin-
like growth factor-1 (IGF-1) [16]. This receptor, in its do-
main of tyrosine kinase located in beta-subunits, shows
an amino acid structure the same as the insulin recep-
tor in 80% of cases. Insulin (mainly hyperinsulinaemic
states) may stimulate the IGF-1 receptor and vice-ver-
sa. This regulatory interchange plays an important role
in foetal development. It could also be responsible for
the increased risk of neoplastic proliferation in adults,
mainly in diabetes mellitus type 2, connected with in-
sulin resistance and hyperinsulinaemia [17–19].
The metabolic effects of insulin differ with respect
to the functional specialization of the cells. They are
dependent on the actions of molecules mediating the
insulin signal transduction to the specific genes in stri-
ated muscle cells and in adipocytes [22–25]. PI-3K in-
creases the cellular glucose utilization primarily by stim-
ulating the formation and function of the glucotrans-
porters GLUT4 and GLUT1. In this way the cells increase
the glycogenogenesis (muscle) and lipidogenesis (adi-
pocytes) [23–25]. At the same time, PI-3K increases the
vitality of cells. The PI-3K mediated stimulation of the
molecules mTOR (rapamycin dependent molecule)
augments the synthesis of proteins. The molecule GRB-
2 stimulates the mitogen activated kinases (MAPK) and
the transcription of respective genes [16].
Figure 2. Impairment of cellular glucose transport is the rate-
controlling step responsiblefor reduced muscle glycogen synthesis
in patients with type 2 diabetes mellitus (adapted, Shulman G.I.:
Clin Invest 2000; 106: 171–176
Rycina 2. Upośledzenie dokomórkowego transportu glukozy jest
głównym czynnikiem powodującym zmniejszenie syntezy
glikogenu w mięśniach u chorych na cukrzycę typu 2 (na podstawie:
Shulman GI. Clin Invest 2000; 106: 171–176
Figure 3. Proposed mechanism for fatty acids-induced insulin
resistance in human skeletal muscle (adapted: Shulman GI. J Clin
Invest 2000; 106: 171–176)
Rycina 3. Mechanizm rozwoju insulinooporności indukowanej
przez wolne kwasy tłuszczowe w ludzkim mięśniu szkieletowym
(na podstawie: Shulman GI. J Clin Invest 2000; 106: 171–176)
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Table V. Insulin regulatory actions on metabolic processes — the role of GLUT4 [28–31]
Tabela V. Regulacja procesów metabolicznych przez insulinę — rola GLUT4 [28–31]
• The intake of glucose by the cells increases — predominantly by the striated muscle, and adipose tissue is strictly coordinated
with the decrease of glucose production and release from the liver. This is also the effect of exogenous insulin;
• At the same time, resulting from the action of insulin, the increase of the production of alfa-glycerolphosphate facilitates the
re-esterification of free fatty acids and inhibits the ketogenesis;
• in the striated muscle and adipose tissue cells, insulin causes the redistribution (translocation) of the glucose transporters,
mainly GLUT4, to the cellular membrane;
• transmembrane glucose transport from the extracellular space to the interior of the cells, and the glucose utilization is increased
Based on the examples described above, it can be
stated that the structural (genetic) or functional (relat-
ed to environment) changes in any of the signal mole-
cules may limit the signalling process and cause resis-
tance to insulin [5, 6, 26]. This can be observed in clini-
cal conditions as the result of the signalling defects in
the liver, striated muscle, and adipocytes as well as in
pancreatic beta cells [22–27]. In this area, many inter-
esting studies have proved the primary significance of
the GLUT4 formation and function. It could be limited,
for example, to making only the striated muscle cells
insulin resistant. The reason for such perturbation is the
intracellular hyper accumulation of free fatty acids,
DAG, and other lipids, depressing the action of the dif-
ferent signalling molecules (IRS-1, PI-3K) and the in-
crease of activity of the protein kinases C family. These
abnormalities inhibit the translocation of GLUT4 in stri-
ated muscle and slow down the transport of glucose to
the cells [28] (Table V, Fig. 4).
The role of intracellular
hexokinase and glucokinase
The glucose molecules, after being transported through
the cellular membrane, immediately enter the metabolic
pathways. The first, regulatory step is the phosphory-
lation of glucose. This reaction is catalysed by two sim-
ilar enzymes: hexokinase and glucokinase. The prod-
uct of this reaction (the glucose-6 phosphate) enters the
glycolysis metabolic pathway. In this way it regulates
the intensity of the process depending on the glycoly-
sis pathway as the tricarboxylic acid cycle in the mito-
chondrial matrix and inner mitochondrial membrane
[12]. Free glucose is almost nonexistent in intracellular
Figure 4. A. Typical example of the GLUT4 expression assessment in lymphocytes of the peripheral blood with flow cytometry in the
case of diabetes mellitus type 2: R.W., male, aged 58 years, HbA1C  8.9%, 17.38% of lymphocytes expressed the GLUT4; B. After
12 weeks of diabetes mellitus type 2 therapy, in this case with diet and sulphonylurea,a significant decrease of the GLUT4 expression
from 17.38% to 2.57% was observed.This phenomenon was connected with  adecrease of HbA1C below 6.5%
Rycina 4. A.Typowy przykład oceny ekspresji GLUT4 w limfocytach krwi obwodowej metodą cytometrii przepływowej u chorego na
cukrzycę typu 2: R.W., mężczyzna, wiek 58 lat, HbA1C — 8,9%, ekspresja GLUT4 w 17,38% limfocytów; B. Ten sam chory; po 12 ty-
godniach leczenia dietą i pochodną sulfonylomocznika stwierdzono istotne zmniejszenie ekspresji GLUT4 z 17,38% do 2,57%. Jednocześnie
nastąpiło obniżenie HbA1C poniżej 6,5%
A B
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space. These metabolic processes keep the difference
in concentration of glucose in extracellular and in in-
tracellular space and stimulate, in a secondary way, cel-
lular glucose transport.
Conclusions
The resistance of the cell to insulin and the consequent
impairment of cellular glucose utilization should be re-
garded as an important and frequent pathogenetic
mechanism of several clinical symptomatic syndromes
including, in the first place, type 2 diabetes mellitus. It
may also play a role as a risk factor coexisting with oth-
er morbid influences, as in atherosclerosis first of all.
For these reasons, diagnostic and specific therapy of
insulin resistance is developing dynamically.
Resistance to insulin is primarily connected with
a decrease of cellular glucose transport and is related,
in a more or less specific way, to the structural and func-
tional disturbances of the specific molecules forming the
signalling pathway for insulin action from its receptor
downstream to expression of more than 100 genes. On
the basis of new research and data, it is now possible to
diagnose resistance to insulin as resulting from the ab-
normalities in the specific molecules of the insulin sig-
nalling pathway. They may have a more general char-
acter, involving the whole organism, or may be limited
to one organ or to one or more metabolic or prolifera-
tive processes. In addition, the molecular aetiology of
resistance to insulin may have different mechanisms:
genetic, metabolic, endocrine, pharmacological, or tox-
ic. The aetiological and clinical classification of insulin
resistance is therefore pending.
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